4 results about "Human parvovirus" patented technology

The invention relates to a reagent and a method for simultaneously detecting three genotypes of human parvovirus B19. The reagent comprises (1) a primer group taking an NS1 gene and a VP1 gene as target genes; and (2) a fluorescent probe which is matched with the primer group and is used for Q-PCR (Quantitative Polymerase Chain Reaction) detection. The three genotypes of the human parvovirus B19 are a human parvovirus B19 I type, a human parvovirus B19 II type and a human parvovirus B19 III type.

The present application relates to compositions and methods for detecting human parvovirus nucleic acid and for detecting hepatitis A virus nucleic acid in single or multiplex assays. In particular, the present application discloses nucleic acid oligomers specific for human parvovirus genomic DNA. Also disclosed is an assay for amplifying and detecting nucleic acid of human parvovirus genotypes 1, 2 and 3 in a biological specimen. Also disclosed are compositions for amplifying and detecting the presence of genomic DNA of human parvovirus genotypes 1, 2 and 3 in a human biological specimen.

The present application relates to compositions and methods for detecting human parvovirus nucleic acid and for detecting hepatitis A virus nucleic acid in single or multiplex assays. In particular, the present application discloses nucleic acid oligomers specific for human parvovirus genomic DNA. Also disclosed is an assay for amplifying and detecting nucleic acid of human parvovirus genotypes 1, 2 and 3 in a biological specimen. Also disclosed are compositions for amplifying and detecting the presence of genomic DNA of human parvovirus genotypes 1, 2 and 3 in a human biological specimen.

The invention belongs to the technical field of cell replication inhibition, and particularly relates to a method for inhibiting replication of human parvovirus B19 in cells. According to the method, the aim of inhibiting the replication of the human parvovirus B19 in the cells can be remarkably achieved by inhibiting CRM1 or mutating any one of the 255th to 263th amino acids and / or the 285th to 297th amino acids in an NS1 protein amino acid sequence. For example, by taking an NS1 defective genome M20-NS1 as a core and combining with pHelper through a functional complementation experiment, it is found that wild type NS1 (3 * FlagB19-NS1) can restore virus DNA replication, RNA transcription and generation of filial generation virus particles; and the mutant blocks the CRM1-mediated nuclear output pathway, so that the virus genome replication level is reduced by 30%-95%, the RNA transcription is reduced by 20%-80%, and the generation efficiency of filial generation virus particles is reduced by 86%.